Abbott Laboratories: Not Passing The Test, After Buying Test Maker Exact Sciences [Seeking Alpha]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Seeking Alpha
Abbott's diversified business, strong organic growth, and consistent dividend hikes remain positives, but the Exact Sciences deal adds significant leverage and near-term earnings dilution. The acquisition is expected to enhance Abbott's diagnostics segment, but meaningful earnings accretion is only anticipated from 2028 onward, after initial dilution. Current valuation and deal risks make Abbott less compelling at present; a lower share price or smaller premium would increase long-term appeal. jetcityimage/iStock Editorial via Getty Images Shares of Abbott Laboratories ( ABT have seen a small negative price reaction in response to a larger deal for its smaller diagnostic peer Exact Sciences ( EXAS , taking place at a revenue premium on the back of stronger growth, although More on my IG service If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A,
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Grail: Downgraded From Speculative Buy To Hold As The Stock Price Appreciated Faster Than Expected [Seeking Alpha]Seeking Alpha
- Exact Sciences (NASDAQ:EXAS) was given a new $105.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSNPR Newswire
- HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSNGlobeNewswire
EXAS
Earnings
- 11/3/25 - Beat
EXAS
Sec Filings
- 11/26/25 - Form DEFA14A
- 11/24/25 - Form DEFA14A
- 11/21/25 - Form 4
- EXAS's page on the SEC website